Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults DOI Open Access
Marco Infante, F Silvestri, Nathalia Padilla

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1303 - 1303

Published: Feb. 15, 2025

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the immune-mediated destruction of insulin-producing pancreatic beta cells, resulting in lifelong need for exogenous insulin. Over last few years, overweight and obesity have recently emerged as growing health issues also afflicting patients with T1D. In this context, term "double diabetes" has been coined to indicate T1D who family history type 2 (T2D) and/or are affected insulin resistance overweight/obesity metabolic syndrome. At same time, use second-generation incretin analogs semaglutide tirzepatide substantially increased on global scale over given remarkable clinical benefits these drugs (in terms glucose control weight loss) T2D overweight/obesity. Although glucagon-like peptide-1 (GLP-1) receptor agonists novel dual GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 agonist currently not approved treatment T1D, body evidence years shown that medications may serve valid add-on treatments substantial efficacy improving control, promoting loss, preserving residual beta-cell function providing other beneficial effects double latent adults (LADA). This manuscript aims comprehensively review available literature (mostly consisting real-world studies) regarding safety therapeutic (for different purposes) (at stages disease), LADA.

Language: Английский

Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases DOI
Yuming Sun, Qian Zhou,

Lorraine Edna Onzere

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2025, Volume and Issue: 19(1), P. 103186 - 103186

Published: Jan. 1, 2025

Language: Английский

Citations

3
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs DOI Creative Commons

Xing Wan,

Jingyuan Ma,

He Bai

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 140 - 140

Published: Jan. 17, 2025

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), syndrome. However, effective treatment strategies for NAFLD are still lacking. In recent years, progress been made in understanding pathogenesis of NAFLD, identifying multiple therapeutic targets providing new directions drug development. This review summarizes advances focusing on mechanisms action natural products, small-synthetic-molecule drugs, combination therapy strategies. aims to provide insights treating NAFLD.

Language: Английский

Citations

2
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot DOI
Eda Kaya,

Wing‐Kin Syn,

Paul Manka

et al.

Current Opinion in Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Purpose of review Obesity and type 2 diabetes mellitus (T2DM) are significant global health challenges, closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in treating T2DM obesity, but their potential for managing MASLD is still being explored. This aims examine the current progress using GLP-1RAs treatment evaluate emerging dual triple hormonal as future therapeutic options. Recent findings been effective controlling blood sugar levels, promoting weight loss, improving cardiovascular kidney function. Furthermore, they benefits function patients with MASLD. GLP-1, a key incretin hormone, influences glucose metabolism, appetite, insulin sensitivity while affecting gastric emptying potentially reducing fat deposition liver. developments include various formulations different administration dosing options, expanding use. Summary become central management T2DM, possibly due ability lower HbA1c, aid reduction, provide protection. As research continues, next evolution incretin-based therapies, offering promising new strategies addressing future.

Language: Английский

Citations

2
ACUTE HYPERGLYCEMIA INDUCES PODOCYTE APOPTOSIS BY MONOCYTE TNF-α RELEASE, A PROCESS ATTENUATED BY VITAMIN D AND GLP-1 RECEPTOR AGONISTS DOI Creative Commons
Rong M. Zhang,

Jisu Oh,

Burton M. Wice

et al.

The Journal of Steroid Biochemistry and Molecular Biology, Journal Year: 2025, Volume and Issue: unknown, P. 106676 - 106676

Published: Jan. 1, 2025

Language: Английский

Citations

1
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence DOI Creative Commons
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes

et al.

Receptors, Journal Year: 2025, Volume and Issue: 4(1), P. 2 - 2

Published: Jan. 26, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) obesity. These agents mimic the action of endogenous incretin glucagon-like (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to neuroprotective effects, suggesting their potential as treatment neurodegenerative disorders, such Alzheimer’s disease (AD). AD T2DM share several common pathophysiological mechanisms, resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction. shared mechanisms suggest that therapeutic targeting metabolic dysfunction may also be beneficial conditions. Preclinical studies on in models, both vitro vivo, demonstrated promising reductions amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, enhanced neuronal survival. Despite encouraging results from preclinical challenges need addressed before can widely used treatment. Ongoing clinical trials investigating cognitive benefits patients, aiming establish role a option AD. This review aimed examine current literature GLP-1

Language: Английский

Citations

1
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis DOI Creative Commons
Hanieh Radkhah, Shiva Rahimipour Anaraki, Peyvand Parhizkar Roudsari

et al.

Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity, Journal Year: 2025, Volume and Issue: 30(1)

Published: Feb. 1, 2025

Abstract Purpose Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating therapeutic promise, particularly for binge disorder (BED). This systematic review evaluates the of GLP-1 BED, focusing weight management and behaviors. Methods A search PubMed, Scopus, Web Science, Cochrane Library, along with manual searches, identified assessing BED patients up to November 8, 2024. Observational clinical trials meeting inclusion criteria were analyzed. Results Five (182 participants) included. Patients receiving experienced greater loss (− 3.81 kg; 95% CI − 5.14 2.49; p < 0.01, I 2 : 59.88%) compared controls. significantly reduced BMI 1.48 kg/m ) waist circumference 3.14 cm). Binge Eating Scale (BES) scores improved 8.14 points; 13.13 3.15; 0.01), though heterogeneity was noted. Conclusions underscores role management. However, given limited data, especially concerning EDs other than long-term these medications, further comprehensive are recommended evaluate impact various different across diverse demographic groups. Level evidence I, randomized controlled trials.

Language: Английский

Citations

1
G-Protein-Coupled Receptor (GPCR) Signaling and Pharmacology in Metabolism: Physiology, Mechanisms, and Therapeutic Potential DOI Creative Commons
Y. Cho, Soyeon Kim,

Pan-Kyung Kim

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 291 - 291

Published: Feb. 15, 2025

G-protein coupled receptors (GPCRs), the largest family of integral membrane proteins, enable cells to sense and appropriately respond environment through mediating extracellular signaling intercellular messenger molecules. GPCRs' pairing with a diverse array G protein subunits related downstream secondary messengers, combined their ligand versatility-from conventional peptide hormone numerous bioactive metabolites, allow GPCRs comprehensively regulate metabolism physiology. Consequently, have garnered significant attention for therapeutic potential in metabolic diseases. This review focuses on six GPCRs, GPR40, GPR120, GLP-1R, ß-adrenergic (ADRB1, ADRB2, ADRB3), GLP-1R recognized as prominent regulator system-level metabolism, while roles GPR120 central carbon energy homeostasis are increasingly appreciated. Here, we discuss physiological functions current pharmacological landscape, intricacies pathways via ß-arrestin activation. Additionally, limitations existing GPCR-targeted strategies treating diseases offer insights into future perspectives advancing GPCR pharmacology.

Language: Английский

Citations

1
Risk of Glaucoma in Non-Diabetic Patients using a Glucagon Like Peptide-1 Receptor Agonist DOI
Pranav Vasu, Emily Dorairaj, Robert N. Weinreb

et al.

Ophthalmology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities DOI Creative Commons
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon

et al.

Peptides, Journal Year: 2025, Volume and Issue: 187, P. 171380 - 171380

Published: March 11, 2025

Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).

Language: Английский

Citations

1
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study DOI

Chia-Chih Kuo,

Min‐Hsiang Chuang, Chun‐Hsien Li

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 27, 2024

Language: Английский

Citations

4